Sabine Mueller
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sabine Mueller has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Sebastian M. Waszak
School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
98 shared publications - Cassie Kline
Division of Oncology The Children's Hospital of Philadelphia Philadelphia Pennsylvania USA
96 shared publications - Adam Resnick
Center for Data-Driven Discovery in Biomedicine, Children’s Hospital of Philadelphia
94 shared publications - Javad Nazarian
University Children’s Hospital, Zurich
81 shared publications - Carl Koschmann
Department of Pediatrics, University of Michigan Medical School , Ann Arbor, Michigan
79 shared publications - Matthew D. Dun
University of Newcastle
76 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (9)
Efficacy Study of Vemurafenib in Children With Recurrent or Progressive BRAF V600E - or BRAF InsT -Mutant Brain Tumors: PNOC002
Purpose: Pediatric gliomas constitute the most prevalent central nervous system tumors in children, and aberrations in BRAF signaling contribute to their pathogenesis by disrupting the MAPK pathway. Targeted inhibition of this pathway using agents such as vemurafenib may hold therapeutic promise. Patients and Methods: PNOC002 was a multicenter trial conducted through the Pediatric Neuro-Oncology Consortium in patients younger than 25 years with recurrent or progressive BRAF V600E -mutant brain tumors. This combined phase 0/1 study aimed to establish the recommended phase II dose (RP2D) and assess preliminary efficacy, including tumor growth trajectories and rebound (defined as ≥25% increase in lesion size within 6 months, usually within 3 months, of stopping therapy). Results: Thirty-patients (range, 3-23 years) were treated at the RP2D of 550 mg/m 2 twice a day: 22 low-grade glioma (LGG) and 8 high-grade glioma (HGG). PFS at 6 months (PFS6) for the entire cohort was 80% (95% CI, 67 to 96). In patients with LGG, PFS6 was higher at 86% (95% CI, 73 to 100), compared with 63% (95% CI, 37 to 100) in patients with HGG. The best responses were stable disease (13 patients) and partial responses (13 patients). Four patients experienced PD, with three patients in the HGG cohort. Responsiveness varied by lesion type, with cystic lesions showing a larger and longer-lasting decrease in tumor size than solid lesions. Of 13 patients with LGG who discontinued treatment and had follow-up imaging, 3 (23%) experienced rebound within 78-97 days. The most common grade 3 adverse event was maculopapular rash (57%). Conclusion: Vemurafenib showed efficacy in children with recurrent or progressive BRAF V600E -mutant brain tumors with acceptable toxicity. However, the rebound rate of 23% warrants further investigation.
- 1 September 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (9)
Open AccessEfficacy Study of Vemurafenib in Children With Recurrent or Progressive BRAF V600E - or BRAF InsT -Mutant Brain Tumors: PNOC002
Purpose: Pediatric gliomas constitute the most prevalent central nervous system tumors in children, and aberrations in BRAF signaling contribute to their pathogenesis by disrupting the MAPK pathway. Targeted inhibition of this pathway using agents such as vemurafenib may hold therapeutic promise. Patients and Methods: PNOC002 was a multicenter trial conducted through the Pediatric Neuro-Oncology Consortium in patients younger than 25 years with recurrent or progressive BRAF V600E -mutant brain tumors. This combined phase 0/1 study aimed to establish the recommended phase II dose (RP2D) and assess preliminary efficacy, including tumor growth trajectories and rebound (defined as ≥25% increase in lesion size within 6 months, usually within 3 months, of stopping therapy). Results: Thirty-patients (range, 3-23 years) were treated at the RP2D of 550 mg/m 2 twice a day: 22 low-grade glioma (LGG) and 8 high-grade glioma (HGG). PFS at 6 months (PFS6) for the entire cohort was 80% (95% CI, 67 to 96). In patients with LGG, PFS6 was higher at 86% (95% CI, 73 to 100), compared with 63% (95% CI, 37 to 100) in patients with HGG. The best responses were stable disease (13 patients) and partial responses (13 patients). Four patients experienced PD, with three patients in the HGG cohort. Responsiveness varied by lesion type, with cystic lesions showing a larger and longer-lasting decrease in tumor size than solid lesions. Of 13 patients with LGG who discontinued treatment and had follow-up imaging, 3 (23%) experienced rebound within 78-97 days. The most common grade 3 adverse event was maculopapular rash (57%). Conclusion: Vemurafenib showed efficacy in children with recurrent or progressive BRAF V600E -mutant brain tumors with acceptable toxicity. However, the rebound rate of 23% warrants further investigation.
- 8 June 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (10) , 2313-2335
BRAF-altered glioma in adults and children: A Society for Neuro-Oncology and European Association of Neuro-Oncology consensus review on clinical management and future directions
Oncogenic BRAF alterations occur in a subset of diffuse gliomas across WHO grades and are increasingly identified through modern molecular diagnostics. In addition to standard glioma therapies, targeted treatments are available for patients with BRAF-altered glioma, supported by variable evidence spanning randomized trials, single-arm studies, and real-world evidence. This joint consensus review from the Society for Neuro-Oncology (SNO) and the European Association of Neuro-Oncology (EANO) synthesizes current knowledge on the diagnosis and management of BRAF-altered gliomas across age groups, tumor grades, and lines of therapy. Particular emphasis is placed on expert consensus in clinical scenarios where high-quality trial evidence remains limited. The review addresses rationale testing for BRAF alterations, selection, and monitoring of targeted therapies, management of treatment-related toxicities, approaches to resistance, and priorities for future research. It aims to provide practical, evidence-based guidance for clinicians while highlighting gaps to inform prospective studies.
- 8 June 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (10) , 2313-2335
BRAF-altered glioma in adults and children: A Society for Neuro-Oncology and European Association of Neuro-Oncology consensus review on clinical management and future directions
Oncogenic BRAF alterations occur in a subset of diffuse gliomas across WHO grades and are increasingly identified through modern molecular diagnostics. In addition to standard glioma therapies, targeted treatments are available for patients with BRAF-altered glioma, supported by variable evidence spanning randomized trials, single-arm studies, and real-world evidence. This joint consensus review from the Society for Neuro-Oncology (SNO) and the European Association of Neuro-Oncology (EANO) synthesizes current knowledge on the diagnosis and management of BRAF-altered gliomas across age groups, tumor grades, and lines of therapy. Particular emphasis is placed on expert consensus in clinical scenarios where high-quality trial evidence remains limited. The review addresses rationale testing for BRAF alterations, selection, and monitoring of targeted therapies, management of treatment-related toxicities, approaches to resistance, and priorities for future research. It aims to provide practical, evidence-based guidance for clinicians while highlighting gaps to inform prospective studies.
- 22 May 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
Point/Counterpoint: Dordaviprone for diffuse midline glioma - A landmark approval or a premature step?
Lay Summary: The United States (US) Food and Drug Administration (FDA) recently granted accelerated approval to dordaviprone (ONC201, ModeysoTM) for patients with H3 K27M–altered diffuse midline glioma, a rare and aggressive brain tumor with very few treatment options. This Point/Counterpoint editorial discusses what this decision means for science, regulation, and patient care. Accelerated approval allows the FDA to make promising treatments available sooner for serious diseases based on early signs of benefit, such as tumor shrinkage or how long patients respond to treatment. However, additional studies are still required to confirm that the drug truly improves outcomes. In this case, the approval was based on early studies and expanded-access programs that showed the drug may help a subset of patients. Important questions remain. Most of the data used for approval came from non-randomized studies, and it is unclear how well the drug works in newly diagnosed patients or in related tumors such as diffuse intrinsic pontine glioma (DIPG) and spinal cord tumors. We argue that this approval should be seen as conditional, an important step that may speed up research on drug combinations, biomarkers, and better clinical trials, while still requiring strong evidence. The ongoing ACTION trial (NCT05580562) will be critical for confirming the benefit of the drug and guiding how it should be used in practice.
- 22 May 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
Point/Counterpoint: Dordaviprone for diffuse midline glioma - A landmark approval or a premature step?
Lay Summary: The United States (US) Food and Drug Administration (FDA) recently granted accelerated approval to dordaviprone (ONC201, ModeysoTM) for patients with H3 K27M–altered diffuse midline glioma, a rare and aggressive brain tumor with very few treatment options. This Point/Counterpoint editorial discusses what this decision means for science, regulation, and patient care. Accelerated approval allows the FDA to make promising treatments available sooner for serious diseases based on early signs of benefit, such as tumor shrinkage or how long patients respond to treatment. However, additional studies are still required to confirm that the drug truly improves outcomes. In this case, the approval was based on early studies and expanded-access programs that showed the drug may help a subset of patients. Important questions remain. Most of the data used for approval came from non-randomized studies, and it is unclear how well the drug works in newly diagnosed patients or in related tumors such as diffuse intrinsic pontine glioma (DIPG) and spinal cord tumors. We argue that this approval should be seen as conditional, an important step that may speed up research on drug combinations, biomarkers, and better clinical trials, while still requiring strong evidence. The ongoing ACTION trial (NCT05580562) will be critical for confirming the benefit of the drug and guiding how it should be used in practice.
- Open Access
- 19 May 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (9) , 2110-2122
Tempered optimism: Advances in the precision medicine era for pediatric low-grade glioma
The clinical trial landscape of molecularly targeted treatments for pediatric low-grade glioma (pLGG) has created an exciting and hopeful era for both patients and clinicians alike. Despite numerous clinical trials investigating the use of targeted agents for pLGG, only two oral precision-based regimens for pLGG have received federal agency approval. However, enthusiasm surrounding recently completed early phase clinical trials has resulted in increased off-label prescribing practices beyond the federally-approved indications, despite a lack of phase 3 clinical trial data and an incomplete understanding of the long-term radiographic, functional outcomes, and toxicity for both approved and experimental therapies. These gaps in knowledge are critically important to consider when selecting therapies for patients with pLGG, as the prevention and reduction of late effects in pLGG survivors is crucial to prevent long-term morbidity. In this editorial by the clinical working group of the International pLGG Coalition, we discuss the landscape of molecularly targeted therapies for pLGG, outline the unanswered questions for the use of novel therapies in the management of pLGG, review the risks and benefits of early off-label use of targeted agents, and discuss the importance of patience and evidence-based clinical practice in the rapidly evolving era of precision medicine.
- 19 May 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (9) , 2110-2122
Open AccessTempered optimism: Advances in the precision medicine era for pediatric low-grade glioma
The clinical trial landscape of molecularly targeted treatments for pediatric low-grade glioma (pLGG) has created an exciting and hopeful era for both patients and clinicians alike. Despite numerous clinical trials investigating the use of targeted agents for pLGG, only two oral precision-based regimens for pLGG have received federal agency approval. However, enthusiasm surrounding recently completed early phase clinical trials has resulted in increased off-label prescribing practices beyond the federally-approved indications, despite a lack of phase 3 clinical trial data and an incomplete understanding of the long-term radiographic, functional outcomes, and toxicity for both approved and experimental therapies. These gaps in knowledge are critically important to consider when selecting therapies for patients with pLGG, as the prevention and reduction of late effects in pLGG survivors is crucial to prevent long-term morbidity. In this editorial by the clinical working group of the International pLGG Coalition, we discuss the landscape of molecularly targeted therapies for pLGG, outline the unanswered questions for the use of novel therapies in the management of pLGG, review the risks and benefits of early off-label use of targeted agents, and discuss the importance of patience and evidence-based clinical practice in the rapidly evolving era of precision medicine.
- Open Access
- 18 May 2026
- Published by Springer Nature in BMC Medicine
- Vol. 24 (1)
Generative AI for spatial tumor growth on MRI: a proof-of-principle study in pediatric diffuse midline glioma
Background: Magnetic resonance imaging (MRI) is a cornerstone of non-invasive diagnosis and response monitoring in neuro-oncology, and predictions of spatial tumor progression conditioned on the patients’ anatomy are increasingly important. We present a proof-of-principle of personalized spatial tumor progression on MRI through generative AI, focusing on pediatric Diffuse Midline Glioma (DMG). Methods: We employed guided Denoising Diffusion Implicit Models (DDIM) to model anatomical tumor growth in pediatric DMGs on MRI. Multiparametric scans from adult ( n = 1,251) and pediatric ( n = 144) patients from the BraTS23 challenge were used to train a slice-based framework, conditioned on baseline scans and a target tumor size. Repeated image generations produce probabilistic tumor growth maps highlighting likely regions of progression. The realism of the generated MRIs was evaluated quantitatively and qualitatively through expert assessment. Spatial growth predictions were validated against an independent dataset of longitudinal MRI scans from a multi-institutional pre-radiotherapy DMG dataset ( n = 178 paired slices). Results: We generated anatomically coherent, patient-specific T2-FLAIR (fluid-attenuated inversion recovery) MRI axial slices. Quantitative measures and expert evaluations confirmed the high quality of the generated images, which trained radiologists were unable to reliably distinguish from real scans (accuracy 0.53 ± 0.03). While radiomic features analyses showed good agreement (83% non-significant features) between synthetic and real images, a classifier detected subtle pixel-wise differences (accuracy of 0.69). Tumor growth probability maps aligned well with true tumor growth observed in follow-up imaging, obtaining a mean continuous DICE score of 0.79 ± 0.13. Conclusions: We present guided DDIMs as a predictive tool for spatial tumor growth, illustrated for the progression of DMGs, that demonstrates potential for its integration in personalized radiotherapy planning. Our comprehensive image quality analysis highlights the importance of carefully evaluating synthetic data and its integration in research and clinical workflows.
- 18 May 2026
- Published by Springer Nature in BMC Medicine
- Vol. 24 (1)
Open AccessGenerative AI for spatial tumor growth on MRI: a proof-of-principle study in pediatric diffuse midline glioma
Background: Magnetic resonance imaging (MRI) is a cornerstone of non-invasive diagnosis and response monitoring in neuro-oncology, and predictions of spatial tumor progression conditioned on the patients’ anatomy are increasingly important. We present a proof-of-principle of personalized spatial tumor progression on MRI through generative AI, focusing on pediatric Diffuse Midline Glioma (DMG). Methods: We employed guided Denoising Diffusion Implicit Models (DDIM) to model anatomical tumor growth in pediatric DMGs on MRI. Multiparametric scans from adult ( n = 1,251) and pediatric ( n = 144) patients from the BraTS23 challenge were used to train a slice-based framework, conditioned on baseline scans and a target tumor size. Repeated image generations produce probabilistic tumor growth maps highlighting likely regions of progression. The realism of the generated MRIs was evaluated quantitatively and qualitatively through expert assessment. Spatial growth predictions were validated against an independent dataset of longitudinal MRI scans from a multi-institutional pre-radiotherapy DMG dataset ( n = 178 paired slices). Results: We generated anatomically coherent, patient-specific T2-FLAIR (fluid-attenuated inversion recovery) MRI axial slices. Quantitative measures and expert evaluations confirmed the high quality of the generated images, which trained radiologists were unable to reliably distinguish from real scans (accuracy 0.53 ± 0.03). While radiomic features analyses showed good agreement (83% non-significant features) between synthetic and real images, a classifier detected subtle pixel-wise differences (accuracy of 0.69). Tumor growth probability maps aligned well with true tumor growth observed in follow-up imaging, obtaining a mean continuous DICE score of 0.79 ± 0.13. Conclusions: We present guided DDIMs as a predictive tool for spatial tumor growth, illustrated for the progression of DMGs, that demonstrates potential for its integration in personalized radiotherapy planning. Our comprehensive image quality analysis highlights the importance of carefully evaluating synthetic data and its integration in research and clinical workflows.
- 1 April 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 3 (2)
PNOC014: Phase I Study of Tovorafenib for Children With Relapsed/Recurrent Low-Grade Gliomas and Other Mitogen Activated Protein Kinase Pathway–Activated Tumors
PURPOSE: More than a decade ago, researchers identified tovorafenib as a potential therapeutic option for the most common pediatric benign brain tumor, the KIAA1549:BRAF -fused low-grade glioma. Our study aimed to establish the safety, tolerability, dosing, and preliminary efficacy of this drug. PATIENTS AND METHODS: We conducted a phase I investigator-initiated trial of tovorafenib. Eligible patients were age 1 to 25 years with radiographically recurrent/progressive mitogen-activated protein kinase pathway–altered tumors. The first phase (IA) followed a 3 + 3 design. Based on initial observed responses and pharmacokinetic data, the trial was modified to include phase IB using a subgroup-specific time to event (Sub-TITE) design to better determine dosing within two subgroups defined by body surface area (BSA ≤1.5 m 2 and >1.5 m 2 ). Toxicities were graded according to Common Terminology Criteria for Adverse Events version 5. Response was classified as complete response (CR), partial response (PR), or stable disease (SD). RESULTS: We treated 44 eligible patients (phase IA: 9; phase IB: 35) with high-(n = 6) or low-grade (n = 38) tumors. Pilocytic astrocytoma (n = 19) was the most common diagnosis; KIAA1549:BRAF fusion was the most common molecular alteration (n = 27). No dose-limiting toxicities (DLTs) occurred in phase IA. Phase IB included 6 DLTs: three in each BSA subgroup, all at 530 mg/m 2 /dose, all grade 3. The most common adverse reactions were skin-related. The most common grade 3 adverse event was growth suppression while on treatment. Preliminary response data for 36 evaluable patients in the combined cohorts included 32 patients with CR/PR/SD. Four patients had progressive disease. CONCLUSION: This study established the initial tolerability and preliminary efficacy of oral tovorafenib once every week. The recommended phase II dose was 420 mg/m 2 administered orally, once every week. Growth suppression while on drug was an unexpected side effect.
- 1 April 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 3 (2)
PNOC014: Phase I Study of Tovorafenib for Children With Relapsed/Recurrent Low-Grade Gliomas and Other Mitogen Activated Protein Kinase Pathway–Activated Tumors
PURPOSE: More than a decade ago, researchers identified tovorafenib as a potential therapeutic option for the most common pediatric benign brain tumor, the KIAA1549:BRAF -fused low-grade glioma. Our study aimed to establish the safety, tolerability, dosing, and preliminary efficacy of this drug. PATIENTS AND METHODS: We conducted a phase I investigator-initiated trial of tovorafenib. Eligible patients were age 1 to 25 years with radiographically recurrent/progressive mitogen-activated protein kinase pathway–altered tumors. The first phase (IA) followed a 3 + 3 design. Based on initial observed responses and pharmacokinetic data, the trial was modified to include phase IB using a subgroup-specific time to event (Sub-TITE) design to better determine dosing within two subgroups defined by body surface area (BSA ≤1.5 m 2 and >1.5 m 2 ). Toxicities were graded according to Common Terminology Criteria for Adverse Events version 5. Response was classified as complete response (CR), partial response (PR), or stable disease (SD). RESULTS: We treated 44 eligible patients (phase IA: 9; phase IB: 35) with high-(n = 6) or low-grade (n = 38) tumors. Pilocytic astrocytoma (n = 19) was the most common diagnosis; KIAA1549:BRAF fusion was the most common molecular alteration (n = 27). No dose-limiting toxicities (DLTs) occurred in phase IA. Phase IB included 6 DLTs: three in each BSA subgroup, all at 530 mg/m 2 /dose, all grade 3. The most common adverse reactions were skin-related. The most common grade 3 adverse event was growth suppression while on treatment. Preliminary response data for 36 evaluable patients in the combined cohorts included 32 patients with CR/PR/SD. Four patients had progressive disease. CONCLUSION: This study established the initial tolerability and preliminary efficacy of oral tovorafenib once every week. The recommended phase II dose was 420 mg/m 2 administered orally, once every week. Growth suppression while on drug was an unexpected side effect.
- 1 April 2026
- Published by Springer Nature
- p. 68-79
Mechanistic Learning with Guided Diffusion Models to Predict Spatio-Temporal Brain Tumor Growth
- 1 April 2026
- Published by Springer Nature
- p. 68-79
Mechanistic Learning with Guided Diffusion Models to Predict Spatio-Temporal Brain Tumor Growth
- Open Access
- 6 December 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology Pediatrics
- Vol. 2 (1)
Stereotactic radiosurgery for recurrent primary and metastatic central nervous system malignancies in the pediatric population
Background: The safety and efficacy of stereotactic radiosurgery (SRS) in pediatric malignant central nervous system (CNS) tumors are not well established. This study evaluates disease control and toxicity outcomes following SRS in this population. Methods: 53 SRS treatments in 35 pediatric patients (age ≤ 21) with primary (n = 27) or metastatic (n = 8) CNS malignancies treated between 2000 and 2023 were retrospectively reviewed. Kaplan–Meier and Cox proportional hazards analyses were performed. Results: Median age at SRS was 12 years [interquartile range (IQR): 6.6-16.3]; 71% had prior external beam radiation to the brain. Median follow-up was 33 months. SRS was delivered in a single fraction in 91% (median dose 18 Gy). Median gross tumor volume (GTV) was 1.3cc (IQR: 0.36-4.1) for single-fraction and 23.2cc (IQR: 10.5-23.2) for fractionated SRS. The 1-year local control (LC) rate was 81.4%. 3-year intracranial progression-free survival (IC-PFS) and overall survival were 19.9% and 59.3%, respectively. Distant brain recurrence without local failure occurred in 54% at a median of 8 months. Patients treated for a single lesion had superior 3-year IC-PFS compared with those with 2-4 or ≥5 lesions (29.2% vs 6.7% and 0%, P = .01). Two patients (5%) developed grade ≥3 adverse radiation effects (AREs), both related to treatment effect within 1 year after SRS. No associations were found between ARE and dosimetric parameters or prior radiation. Conclusion: SRS provides effective LC with low toxicity in pediatric malignant CNS tumors. Although there remains a substantial risk of distant CNS failures after SRS, all patients were able to receive additional salvage therapy including re-irradiation.
- 6 December 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology Pediatrics
- Vol. 2 (1)
Open AccessStereotactic radiosurgery for recurrent primary and metastatic central nervous system malignancies in the pediatric population
Background: The safety and efficacy of stereotactic radiosurgery (SRS) in pediatric malignant central nervous system (CNS) tumors are not well established. This study evaluates disease control and toxicity outcomes following SRS in this population. Methods: 53 SRS treatments in 35 pediatric patients (age ≤ 21) with primary (n = 27) or metastatic (n = 8) CNS malignancies treated between 2000 and 2023 were retrospectively reviewed. Kaplan–Meier and Cox proportional hazards analyses were performed. Results: Median age at SRS was 12 years [interquartile range (IQR): 6.6-16.3]; 71% had prior external beam radiation to the brain. Median follow-up was 33 months. SRS was delivered in a single fraction in 91% (median dose 18 Gy). Median gross tumor volume (GTV) was 1.3cc (IQR: 0.36-4.1) for single-fraction and 23.2cc (IQR: 10.5-23.2) for fractionated SRS. The 1-year local control (LC) rate was 81.4%. 3-year intracranial progression-free survival (IC-PFS) and overall survival were 19.9% and 59.3%, respectively. Distant brain recurrence without local failure occurred in 54% at a median of 8 months. Patients treated for a single lesion had superior 3-year IC-PFS compared with those with 2-4 or ≥5 lesions (29.2% vs 6.7% and 0%, P = .01). Two patients (5%) developed grade ≥3 adverse radiation effects (AREs), both related to treatment effect within 1 year after SRS. No associations were found between ARE and dosimetric parameters or prior radiation. Conclusion: SRS provides effective LC with low toxicity in pediatric malignant CNS tumors. Although there remains a substantial risk of distant CNS failures after SRS, all patients were able to receive additional salvage therapy including re-irradiation.
- Open Access
- 2 December 2025
- Vol. 8 (Suppl 2) , ii41-ii58
A new hope: Clinical advances in targeted therapies for pediatric diffuse midline glioma
Diffuse midline glioma (DMG) is an aggressive pediatric brain tumor with a 1%–2% overall survival, largely due to the ineffectiveness of conventional treatments such as chemotherapy and radiotherapy, as well as the inoperability of the tumors because of their critical location and infiltrative diffuse growth. Recent advances in targeted therapies offer new hope, particularly those addressing key molecular characteristics and newly identified cancer dependencies. Among these are histone deacetylase inhibitors (HDACis), receptor tyrosine kinase inhibitors, and novel agents such as ONC201 and unesbulin that target metabolic and epigenetic pathways respectively. In addition, emerging therapies like FACT inhibitors and polyamine pathway inhibitors are showing promise by disrupting critical cancer cell processes. Immunotherapies, including CAR-T cells targeting surface antigens such as GD2 and B7-H3, cancer vaccines, monoclonal antibodies, and oncolytic viruses, are also gaining traction, offering a new approach by harnessing the immune system to attack tumor cells. Despite these advances, challenges such as drug delivery across the blood–brain barrier and therapeutic resistance persist, necessitating the development of combination therapies and innovative delivery methods. Ongoing research is focused on refining these strategies and exploring additional molecular and immunological targets to improve outcomes for children with DMG.
- 2 December 2025
- Vol. 8 (Suppl 2) , ii41-ii58
Open AccessA new hope: Clinical advances in targeted therapies for pediatric diffuse midline glioma
Diffuse midline glioma (DMG) is an aggressive pediatric brain tumor with a 1%–2% overall survival, largely due to the ineffectiveness of conventional treatments such as chemotherapy and radiotherapy, as well as the inoperability of the tumors because of their critical location and infiltrative diffuse growth. Recent advances in targeted therapies offer new hope, particularly those addressing key molecular characteristics and newly identified cancer dependencies. Among these are histone deacetylase inhibitors (HDACis), receptor tyrosine kinase inhibitors, and novel agents such as ONC201 and unesbulin that target metabolic and epigenetic pathways respectively. In addition, emerging therapies like FACT inhibitors and polyamine pathway inhibitors are showing promise by disrupting critical cancer cell processes. Immunotherapies, including CAR-T cells targeting surface antigens such as GD2 and B7-H3, cancer vaccines, monoclonal antibodies, and oncolytic viruses, are also gaining traction, offering a new approach by harnessing the immune system to attack tumor cells. Despite these advances, challenges such as drug delivery across the blood–brain barrier and therapeutic resistance persist, necessitating the development of combination therapies and innovative delivery methods. Ongoing research is focused on refining these strategies and exploring additional molecular and immunological targets to improve outcomes for children with DMG.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
All Supplementary Figures and their captions.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
All Supplementary Figures and their captions.